MET and neoplasm: A kinase inhibitor targeting MET, including the METex14 hopping mutation. Tepotinib, administered once daily, inhibits MET phosphorylation and subsequent downstream signaling pathways to inhibit tumor growth, anchor-independent growth, and MeT-dependent tumor cell migration